ADC Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for ADC Therapeutics (ADCT).

Price Target Range — 12 Quarters

Analyst Consensus — 6 Analysts

3Buy

3Hold

Consensus RatingOverweight# Analysts6Avg. Consensus PT$6Upside to Avg. PT+232.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 17, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$10→$5
Jun 8, 2026	HC Wainwright & Co.	Robert Burns	Downgrade	Buy→Neutral	—
Jun 4, 2026	RBC Capital	Leonid Timashev	Downgrade	Outperform→Sector Perform	$6→$2
May 5, 2026	RBC Capital	Leonid Timashev	Maintained	Outperform	$6
May 5, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$8
Mar 23, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$7→$8
Oct 16, 2025	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$8→$7
Aug 13, 2025	Guggenheim	Michael Schmidt	Maintained	Buy	$10
Jun 20, 2025	RBC Capital	Leonid Timashev	PT Cut	Outperform	$8→$5
Jun 13, 2025	Guggenheim	Michael Schmidt	PT Raise	Buy	$7→$10
May 15, 2025	RBC Capital	Gregory Renza	Maintained	Outperform	$8
Mar 31, 2025	Guggenheim	Michael Schmidt	PT Cut	Buy	$10→$7
Mar 31, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$8
Mar 7, 2025	Cantor Fitzgerald	Eric Schmidt	Maintained	Overweight	—
Feb 24, 2025	Stephens & Co.	Sudan Loganathan	PT Raise	Overweight	$6→$8
Jan 6, 2025	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$8
Dec 12, 2024	Guggenheim	Michael Schmidt	Maintained	Buy	$10
Dec 11, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	—
Nov 8, 2024	Stephens & Co.	Sudan Loganathan	Initiate	Overweight	$6
Aug 8, 2024	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$8

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5

Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to $5.

Benzinga Newsdesk

This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday

Top Wall Street analysts changed outlook on top names. ADCT downgraded See analysts' views.

Avi Kapoor

PRO
HC Wainwright & Co. Downgrades ADC Therapeutics to Neutral

HC Wainwright & Co. analyst Robert Burns downgrades ADC Therapeutics (NYSE:ADCT) from Buy to Neutral.

Benzinga Newsdesk

PRO
RBC Capital Downgrades ADC Therapeutics to Sector Perform, Lowers Price Target to $2

RBC Capital analyst Leonid Timashev downgrades ADC Therapeutics (NYSE:ADCT) from Outperform to Sector Perform and lowers the price target from $6 to $2.

Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target

RBC Capital analyst Leonid Timashev reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $6 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $8 price target.

Benzinga Newsdesk

ADC Therapeutics SA

뉴스

파트너 / 기고자

벤징가 글로벌

ADC Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5

This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday

PRO
HC Wainwright & Co. Downgrades ADC Therapeutics to Neutral

PRO
RBC Capital Downgrades ADC Therapeutics to Sector Perform, Lowers Price Target to $2

PRO
RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target

People Also Watch

People Also Watch

ADC Therapeutics SA

뉴스

파트너 / 기고자

벤징가 글로벌

ADC Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5

This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday

PROHC Wainwright & Co. Downgrades ADC Therapeutics to Neutral

PRORBC Capital Downgrades ADC Therapeutics to Sector Perform, Lowers Price Target to $2

PRORBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target

PROHC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5

PRO
HC Wainwright & Co. Downgrades ADC Therapeutics to Neutral

PRO
RBC Capital Downgrades ADC Therapeutics to Sector Perform, Lowers Price Target to $2

PRO
RBC Capital Reiterates Outperform on ADC Therapeutics, Maintains $6 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $8 Price Target